Last reviewed · How we verify
REPEVAX® after REVAXIS®
REPEVAX and REVAXIS are inactivated poliovirus vaccines.
REPEVAX and REVAXIS are inactivated poliovirus vaccines. Used for Protection against poliovirus types 1, 2, and 3.
At a glance
| Generic name | REPEVAX® after REVAXIS® |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
They work by introducing inactivated poliovirus antigens to the body, which triggers an immune response and provides immunity against poliovirus infection.
Approved indications
- Protection against poliovirus types 1, 2, and 3
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |